## Note
nid: 1497205982738
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#B&B::03_Biochem::05_Lipids::03_Lipid_Drugs, #AK_Step1_v11::#FirstAid::07_Cardiovascular::05_Pharm::10_Lipid-lowering_Agents::PCSK9_Inhibitors, #AK_Step1_v11::#OME_banner::Basic_Science::09_Cardiac, #AK_Step1_v11::#Physeo::09_Pharm::10_Cardiac::14_PCSK9_Inhibitors, #AK_Step1_v11::#Pixorize::03_Pharm::06_Cardio::PCSK9_Inhibitors_(Alirocumab,_Evolocumab), #AK_Step1_v11::#SketchyPharm::Immunology-&-Biochemistry-Pharmacology::Immuno-suppressives::General-Immunotherapy, #AK_Step1_v11::#UWorld::10000-99999::20000-20999::20921, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::2-RelativelyHighYield
markdown: false

### Text
<div>
  <u>PCSK9</u> Inhibitors ({{c1::<b>alirocumab</b>}} and
  {{c1::<b>evolocumab</b>}}) work by inactivating
  <b>{{c2::LDL}}-receptor degradation</b><b>,</b> resulting in a
  dramatic decrease in <b>{{c2::LDL</b>}}
</div>

### Extra
<span style="-webkit-tap-highlight-color: rgba(0, 0, 0, 0);">PCSK9
is a protease secreted by the liver to degrade LDL receptors, these
mabs bind PCSK9 preventing this from occurring, leading to more LDL
taken in from the bloodstream</span>
<div>
  <img src="paste-284c34437b187bfcbb7ab36ba21dccfa5a55db6b.jpg">
  <div><img src=
  "paste-0f8964e397f8541d6f9b7c8d1980800752f03cf0.jpg"></div>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org/spa/cardiac?ref=anki"><img src=
  "_OME_AnkiFlashcards_Topic_6.png"></a>
</div>

### Additional Resources


### One by one

